Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy By Ogkologos - June 16, 2025 447 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR For Children with Retinoblastoma, Disparities Seen across the Globe March 12, 2020 Fake Amazon Delivery Driver Attempts to Steal Elderly Woman’s Cancer Drugs February 19, 2020 EMA Recommends Extension of Therapeutic Indications for Durvalumab and Adopts a... December 23, 2022 En gran cantidad de casos el exito o examen experto os... August 21, 2023 Load more HOT NEWS Topotecan–Berzosertib Combination Shows Promise against Small Cell Lung Cancer ASCO Annual Meeting 2023: Trastuzumab Deruxtecan Effectively Treats HER2-Expressing Tumors and... Doctors Say Girl Has ‘Vanishing Bones’ That Are Slowly Disappearing From... EMA Recommends Approval of the Marketing Authorisation for Tagraxofusp
